DURECT Corporation Shares Up 5% Following Q4 Results
DURECT Corporation (NASDAQ:DRRX) shares were trading 5% higher Tuesday afternoon following the company’s Q4 results, with EPS of ($0.03) coming in better than the consensus estimate of ($0.05). It’s important to note that the company remains far from earnings and much more of a development story at this stage, as it stays on track in its potentially pivotal P2b AHFIRM trial for AH with enrollment going steady.
Analysts at Oppenheimer provided their views on the company following the quarterly earnings. Despite the earlier pandemic-related challenges, the analysts said they are encouraged by the pace of enrollment with over 100 patients dosed, and 51 clinical sites currently enrolling patients. In addition, the company's Posimir partnership continues to make progress as the first sale of Posimir is still expected in Q2/22. The analysts maintained their Outperform rating and $6 price target on the company’s shares.
| Symbol | Price | %chg |
|---|---|---|
| SIDO.JK | 520 | 0 |
| TSPC.JK | 2180 | -2.29 |
| 000105.KS | 104700 | 0 |
| 000100.KS | 118100 | -1.44 |
DURECT Corporation Shares Up 5% Following Q4 Results
DURECT Corporation (NASDAQ:DRRX) shares were trading 5% higher Tuesday afternoon following the company’s Q4 results, with EPS of ($0.03) coming in better than the consensus estimate of ($0.05). It’s important to note that the company remains far from earnings and much more of a development story at this stage, as it stays on track in its potentially pivotal P2b AHFIRM trial for AH with enrollment going steady.
Analysts at Oppenheimer provided their views on the company following the quarterly earnings. Despite the earlier pandemic-related challenges, the analysts said they are encouraged by the pace of enrollment with over 100 patients dosed, and 51 clinical sites currently enrolling patients. In addition, the company's Posimir partnership continues to make progress as the first sale of Posimir is still expected in Q2/22. The analysts maintained their Outperform rating and $6 price target on the company’s shares.
